Trivascular Technologies, Inc. is a medical device company developing and commercializing technologies to advance minimally invasive treatment of abdominal aortic aneurysms (AAA). The Ovation System, the Company's solution for the treatment of AAA through minimally invasive endovascular aortic repair, or EVAR, is a stent graft platform, providing an alternative to conventional devices. It is designed to specifically address many of the limitations associated with conventional EVAR devices and expand the pool of patients eligible for EVAR. The Company is developing Ovation iX iliac limbs for use with both its Ovation Prime and its Ovation iX and Alto aortic bodies, which are in development. Trivascular is developing Ovation iX aortic bodies for use with both its Ovation Prime and its Ovation iX iliac limbs. The Company is developing an aortic body that together with the iliac limbs makes up the Ovation Alto stent graft.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolNASDAQ:TRIV
CUSIPN/A
Phone+1-707-5438800
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-143.61%
Return on Equity-766.90%
Return on Assets-66.97%
Miscellaneous
EmployeesN/A
Outstanding Shares20,520,000
Market Cap$120.75
Trivascular Technologies (NASDAQ:TRIV) Frequently Asked Questions
What is Trivascular Technologies' stock symbol?
Trivascular Technologies trades on the NASDAQ under the ticker symbol "TRIV."
How were Trivascular Technologies' earnings last quarter?
Trivascular Technologies Inc (NASDAQ:TRIV) announced its earnings results on Monday, November, 9th. The medical device company reported ($0.66) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.71) by $0.05. The medical device company earned $9.50 million during the quarter, compared to analyst estimates of $9.28 million. Trivascular Technologies had a negative net margin of 143.61% and a negative return on equity of 766.90%. The firm's quarterly revenue was up 20.3% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.69) earnings per share. View Trivascular Technologies' Earnings History.
What is the consensus analysts' recommendation for Trivascular Technologies?
0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Trivascular Technologies in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A."
Has Trivascular Technologies been receiving favorable news coverage?
News coverage about TRIV stock has been trending somewhat positive on Saturday, Accern Sentiment reports. Accern rates the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Trivascular Technologies earned a news sentiment score of 0.09 on Accern's scale. They also assigned headlines about the medical device company an impact score of 46.87 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next few days.
How do I buy shares of Trivascular Technologies?
Shares of TRIV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Trivascular Technologies' stock price today?
One share of TRIV stock can currently be purchased for approximately $5.87.
How big of a company is Trivascular Technologies?
Trivascular Technologies has a market capitalization of $120.75 million.
How can I contact Trivascular Technologies?
Trivascular Technologies' mailing address is 3910 Brickway Blvd, SANTA ROSA, CA 95403-1070, United States. The medical device company can be reached via phone at +1-707-5438800.
MarketBeat Community Rating for Trivascular Technologies (NASDAQ TRIV)
MarketBeat's community ratings are surveys of what our community members think about Trivascular Technologies and other stocks. Vote "Outperform" if you believe TRIV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TRIV will underperform the S&P 500 over the long term. You may vote once every thirty days.
